PureTech Health plc

PureTech Health plc is a biotechnology company incorporated in the United Kingdom and headquartered in Boston, Massachusetts, that develops pharmaceutical and biotech solutions across psychiatry, neurology, pulmonology, and oncology. The company's clinical-stage pipeline includes LYT-100 for idiopathic pulmonary fibrosis (Phase 2), LYT-200, an IgG4 monoclonal antibody targeting galectin-9 for solid tumors and hematological malignancies (Phase 1/2), and SPT-300, an oral formulation of allopregnanolone for anxious depression. These programs address unmet medical needs in conditions with limited therapeutic options.

Beyond traditional small-molecule and monoclonal antibody development, PureTech pursues several platform technologies. The company develops oral hydrogels designed to enable peptide therapeutic administration, oral therapies based on defined bacterial consortia currently in Phase 3 development, and genetically engineered hematopoietic stem cell therapies for blood cancers. PureTech also operates a voice-based biomarker technology platform that identifies acoustic changes associated with depression, anxiety, and respiratory disease.

The company operates with 56 full-time employees and is publicly listed on Nasdaq. Its operations are concentrated in the United States, with research and development activities focused on advancing its clinical and preclinical programs through various development stages.